Abstract 5534: Analysis of <i>TERT</i> <i>mutant</i> circulating tumor DNA as a potential biomarker of disease activity in patients with unresectable stage III/IV melanoma receiving immuno-oncology therapies
Mahrukh M. Syeda(NYU Langone Health), David Polsky(New York University), Anna C. Pavlick(Cornell University), Todd Wechter(NYU Langone Health), Yesung Lee(NYU Langone Health), Una Moran(NYU Langone Health), Jeremy Tchack(NYU Langone Health), Yongzhao Shao(New York University), Iman Osman(New York University), Broderick C. Corless(Cornell University), Melissa Wilson(Massachusetts Institute of Technology), George Karlin‐Neumann(Bio-Rad (United States))
Cited by 1
Related Papers
High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number
|Analytical Chemistry|2011|2.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k